Bionxt Solutions
  • About Us
    • About Us
    • Our Team
  • Our Products
    • Point-of-Care Diagnostics
    • Drug Delivery
    • Psychedelics
  • News
  • Investors
    • Investor Information
    • Shareholder Documents
  • Contact
  • Home

Our News & Updates

Latest News!

XPhyto reports excellent Rotigotine in-vitro/ex-vivo results for Parkinson’s disease treatment

Vancouver, Canada, and Uttenweiler, Germany (October 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Read Full Story
Lab Techs looking at a computer header
Show All Press Releases Diagnostics Psychedelics Drug Delivery

Drug Delivery, Press Releases

XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study

Oct 11, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Diagnostics, Press Releases

XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities

Oct 5, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 4, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Press Releases, Psychedelics

XPhyto Files Patent Application for Library of Novel Psychedelic Compounds

Sep 20, 2022

Vancouver, Canada, and Uttenweiler, Germany (September 20, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Diagnostics, Press Releases

XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

Jul 18, 2022

Vancouver, Canada, and Uttenweiler, Germany (July 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Press Releases

Prof. Dr. Raimar Loebenberg receives Leadership Award from the Canadian Society for Pharmaceutical Sciences

Jun 27, 2022

Vancouver, Canada, and Uttenweiler, Germany (June 27, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to congratulate...

Continue Reading

Drug Delivery, Press Releases

XPhyto adds pharmaceutical manufacturing expert Dr. Florian A. Sahr to its European team

Jun 8, 2022

Vancouver, Canada, and Uttenweiler, Germany (June 8, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Drug Delivery, Press Releases

XPhyto reports product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease

May 9, 2022

Vancouver, Canada, and Uttenweiler, Germany (May 9, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Diagnostics, Press Releases

XPhyto, Biosensors market and product developments on platform-based oral dissolvable biosensors for oral health and infectious disease

Apr 12, 2022

Vancouver, Canada, and Uttenweiler, Germany (April 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Drug Delivery, Press Releases

XPhyto reports market and product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease

Apr 4, 2022

Vancouver, Canada, and Uttenweiler, Germany (April 4, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Press Releases, Psychedelics

XPhyto provides progress update on Psychedelic Medicine Programs and Novel Compounds Milestone

Feb 22, 2022

Vancouver, Canada, and Uttenweiler, Germany (February 22, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Press Releases

XPhyto Reports on its Three Primary Business Divisions

Feb 8, 2022

Vancouver, Canada, and Uttenweiler, Germany (February 8, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Diagnostics, Press Releases

XPhyto Executes Covid-ID Lab Sales Contracts with Test Clinics and Pharmacies in Germany as part of Multi-Product Rollout Strategy

Feb 1, 2022

Vancouver, Canada, and Uttenweiler, Germany (February 1, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce...

Continue Reading
Page 1 of 71234567
Scientist looking in magnifying glass XPhyto

Be in the know. Get our press releases and latest news first.

Hear about our latest research, products, exclusive partnerships & more.

Unsubscribe anytime. View our Privacy Policy for additional information.

  • About Bionxt
  • Our Team
  • Our Products
  • Careers
  • Investor Information
  • Company/Investor Presentation
  • Press Releases
  • Request Info
  • Legal Information
  • Cautionary Note
  • Privacy Policy
  • Contact
Xphyto test tubes in laboratory footer
Copyright © 2023 Bionxt Solutions
This website uses cookies and third party services. By clicking “Accept”, you consent to the use of all cookies
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT